Therapeutic potential of HDAC6 inhibitor Tubastatin A in health and diseases: current perspective and future directions

Sonu Rajput; Sumeet Kumar Singh; Poonam Yadav; Amit Khurana; Ralf Weiskirchen; Umashanker Navik

doi:10.1016/j.mmr.2026.100024

Your Location：

Home >

Browse articles >

Therapeutic potential of HDAC6 inhibitor Tubastatin A in health and diseases: current perspective and future directions

REVIEW | Updated：2026-05-11

- Therapeutic potential of HDAC6 inhibitor Tubastatin A in health and diseases: current perspective and future directions
- Therapeutic potential of HDAC6 inhibitor Tubastatin A in health and diseases: current perspective and future directions
- 军事医学研究（英文） 2026年
- Affiliations：
  
  Department of Pharmacology, Central University of Punjab, Bathinda 151401, Punjab, India
  Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (IFMPEGKC), RWTH Aachen University Hospital, D-52074 Aachen, Germany
- Author bio：
  
  Ralf Weiskirchen, rweiskirchen@ukaachen.de
  *Umashanker Navik, usnavik@gmail.com;
- Funds：
  
  the Indo-German Science and Technology Centre(IGSTC/PECFAR/Call 2022/USAK/36/2022-23/Award letter/488);the Paired Early Career Fellowship in Applied Research (PECFAR) fellowship. We also extend our thanks to Bayer Pharmaceuticals(PHD-2023-10682);the Indian Council of Medical Research (ICMR)(ID-2021-8630);the Partnerships for Accelerated Innovation and Research (PAIR) programme under the sanction order(ANRF/PAIR/2025/000029/PAIR)
- DOI：10.1016/j.mmr.2026.100024
  中图分类号：
- 收稿：2025-07-08，
  
  录用：2026-03-23，
  
  纸质出版：2026-04
- Accepted：
Scan QR Code
Sonu Rajput, Sumeet Kumar Singh, Poonam Yadav, 等. Therapeutic potential of HDAC6 inhibitor Tubastatin A in health and diseases: current perspective and future directions[J/OL]. 军事医学研究（英文）, 2026.

Rajput S, Singh SK, Yadav P, Khurana A, Weiskirchen R, Navik U. Therapeutic potential of HDAC6 inhibitor Tubastatin A in health and diseases: current perspective and future directions. Mil Med Res. 2026;13(1):100024.
Sonu Rajput, Sumeet Kumar Singh, Poonam Yadav, 等. Therapeutic potential of HDAC6 inhibitor Tubastatin A in health and diseases: current perspective and future directions[J/OL]. 军事医学研究（英文）, 2026. DOI： 10.1016/j.mmr.2026.100024.

Rajput S, Singh SK, Yadav P, Khurana A, Weiskirchen R, Navik U. Therapeutic potential of HDAC6 inhibitor Tubastatin A in health and diseases: current perspective and future directions. Mil Med Res. 2026;13(1):100024. DOI： 10.1016/j.mmr.2026.100024.

摘要

Abstract

Histone deacetylase 6 (HDAC6) is a unique

predominantly cytoplasmic enzyme that regulates a broad spectrum of cellular and physiological processes

including cell proliferation

migration

intracellular transport

and differentiation. Its distinct structural configuration

comprising two catalytic deacetylase domains and a zinc finger ubiquitin-binding domain (ZnF-BUZ)

enables HDAC6 to deacetylate a variety of non-histone substrates

such as α-tubulin

heat shock protein 90 (Hsp90)

cortactin

and peroxiredoxin (Prdx). Furthermore

HDAC6 plays a key role in cellular stress responses and cell survival by facilitating the clearance of misfolded proteins

inducing autophagy

and modulating the unfolded protein response. Despite its cytoprotective roles

HDAC6 has emerged as a therapeutic target due to its involvement in multiple pathological pathways and age-related disorders. Tubastatin A (Tub A)

a novel and highly selective HDAC6 inhibitor

demonstrates strong therapeutic potential against neurodegenerative

cardiovascular

autoimmune

metabolic

cancer

and other diseases. Tub A enhances the acetylation of both histone and non-histone proteins

thereby modulating gene expression and diverse cellular processes. It shows pharmacological effects

including anti-inflammatory

neuroprotective

anti-diabetic

anti-obesity

anti-oxidant

and other activities. Moreover

preclinical evidence suggests that Tub A effectively regulates multiple pathological pathways by inhibiting HDAC6

which contributes to ameliorating age-related disorders. Therefore

Tub A represents a promising epigenetic modulator with broad therapeutic relevance. Hence

further comprehensive and large-scale investigations are warranted to elucidate its clinical potential and its roles in disease management

as no clinical data related to Tub A activity are available. This review highlights the therapeutic potential of the selective HDAC6 inhibitor Tub A across various pathological conditions

discusses current preclinical findings

and outlines key challenges and future directions for clinical translation.

关键词

Keywords

references

Li Y . Modern epigenetics methods in biological research . Methods . 2021 ; 187 : 104 - 13 .

Tang J , Yan H , Zhuang S . Histone deacetylases as targets for treatment of multiple diseases . Clin Sci (Lond) . 2013 ; 124 ( 11 ): 651 - 62 .

Kouzarides T . Chromatin modifications and their function . Cell . 2007 ; 128 ( 4 ): 693 - 705 .

Cavalli G , Heard E . Advances in epigenetics link genetics to the environment and disease . Nature . 2019 ; 571 ( 7766 ): 489 - 99 .

Farsetti A , Illi B , Gaetano C . How epigenetics impacts on human diseases . Eur J Intern Med . 2023 ; 114 : 15 - 22 .

Zhang L , Lu Q , Chang C . Epigenetics in health and disease . Adv Exp Med Biol . 2020 ; 1253 : 3 - 55 .

Gallinari P , Di Marco S , Jones P , Pallaoro M , Steinkühler C . HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics . Cell Res . 2007 ; 17 ( 3 ): 195 - 211 .

Shu F , Xiao H , Li QN , Ren XS , Liu ZG , Hu BW , et al . Epigenetic and post-translational modifications in autophagy: biological functions and therapeutic targets . Signal Transduct Target Ther . 2023 ; 8 ( 1 ): 32 .

Thiagalingam S , Cheng KH , Lee HJ , Mineva N , Thiagalingam A , Ponte JF . Histone deacetylases: unique players in shaping the epigenetic histone code . Ann N Y Acad Sci . 2003 ; 983 : 84 - 100 .

Yoon S , Eom GH . HDAC and HDAC inhibitor: from cancer to cardiovascular diseases . Chonnam Med J . 2016 ; 52 ( 1 ): 1 - 11 .

Jang S , Choi N , Park JH , Yoo KH . Contribution of histone deacetylases (HDACS) to the regulation of histone and non-histone proteins: implications for fibrotic diseases . BMB reports . 2025 ; 58 ( 8 ): 313 - 24 .

Pickell Z , Williams AM , Alam HB , Hsu CH . Histone deacetylase inhibitors: a novel strategy for neuroprotection and cardioprotection following ischemia/reperfusion injury . J Am Heart Assoc . 2020 ; 9 ( 11 ): e016349 .

Carey N , La Thangue NB . Histone deacetylase inhibitors: gathering pace . Curr Opin Pharmacol . 2006 ; 6 ( 4 ): 369 - 75 .

Yao YL , Yang WM . Beyond histone and deacetylase: an overview of cytoplasmic histone deacetylases and their nonhistone substrates . J Biomed Biotechnol . 2011 ; 2011 : 146493 .

Qu M , Zhang H , Cheng P , Wubshet AK , Yin X , Wang X , et al . Histone deacetylase 6's function in viral infection, innate immunity, and disease: latest advances . Front Immunol . 2023 ; 14 : 1216548 .

Pulya S , Amin SA , Adhikari N , Biswas S , Jha T , Ghosh B . HDAC6 as privileged target in drug discovery: a perspective . Pharmacol Res . 2021 ; 163 : 105274 .

Liang T , Fang H . Structure, functions and selective inhibitors of HDAC6 . Curr Top Med Chem . 2018 ; 18 ( 28 ): 2429 - 47 .

Kawaguchi Y , Kovacs JJ , McLaurin A , Vance JM , Ito A , Yao TP . The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress . Cell . 2003 ; 115 ( 6 ): 727 - 38 .

Dallavalle S , Pisano C , Zunino F . Development and therapeutic impact of HDAC6-selective inhibitors . Biochem Pharmacol . 2012 ; 84 ( 6 ): 756 - 65 .

Li J , Zhang J , Huang X , Jin S , Yu Z , Liu Z , et al . HDAC6 is involved in diabetic nephropathy by regulating TGFβ/SMADS and NF-κB signaling pathways . Biochem Pharmacol . 2025 ; 239 : 116996 .

Youn GS , Lee KW , Choi SY , Park J . Overexpression of HDAC6 induces pro-inflammatory responses by regulating ROS-MAPK-NF-κB/AP-1 signaling pathways in macrophages . Free Radic Biol Med . 2016 ; 97 : 14 - 23 .

Chang P , Li H , Hu H , Li Y , Wang T . The role of HDAC6 in autophagy and NLRP3 inflammasome . Front Immunol . 2021 ; 12 : 763831 .

Liu L , Zhou X , Shetty S , Hou G , Wang Q , Fu J . HDAC6 inhibition blocks inflammatory signaling and caspase-1 activation in LPS-induced acute lung injury . Toxicol Appl Pharmacol . 2019 ; 370 : 178 - 83 .

Li Y , Zhao T , Liu B , Halaweish I , Mazitschek R , Duan X , et al . Inhibition of histone deacetylase 6 improves long-term survival in a lethal septic model . J Trauma Acute Care Surg . 2015 ; 78 ( 2 ): 378 - 85 .

Shen S , Svoboda M , Zhang G , Cavasin MA , Motlova L , McKinsey TA , et al . Structural and in vivo characterization of Tubastatin A, a widely used histone deacetylase 6 inhibitor . ACS Med Chem Lett . 2020 ; 11 ( 5 ): 706 - 12 .

Baumgardt SL , Fang J , Fu X , Liu Y , Xia Z , Zhao M , et al . Genetic deletion or pharmacologic inhibition of histone deacetylase 6 protects the heart against ischaemia/reperfusion injury by limiting tumour necrosis factor alpha-induced mitochondrial injury in experimental diabetes . Cardiovasc Res . 2024 ; 120 ( 12 ): 1456 - 71 .

Çakır I , Hadley CK , Pan PL , Bagchi RA , Ghamari-Langroudi M , Porter DT , et al . Histone deacetylase 6 inhibition restores leptin sensitivity and reduces obesity . Nat Metab . 2022 ; 4 ( 1 ): 44 - 59 .

Lu S , Zhang Y , Kalin JH , Cai L , Kozikowski AP , Pike VW . Exploration of the labeling of [ 11 C ] Tubastatin A at the hydroxamic acid site with [ 11 C ] carbon monoxide . J Labelled Comp Radiopharm . 2016 ; 59 ( 1 ): 9 - 13 .

Wang Z , Leng Y , Wang J , Liao HM , Bergman J , Leeds P , et al . Tubastatin A, an HDAC6 inhibitor, alleviates stroke-induced brain infarction and functional deficits: potential roles of α-tubulin acetylation and FGF-21 up-regulation . Sci Rep . 2016 ; 6 : 19626 .

Butler KV , Kalin J , Brochier C , Vistoli G , Langley B , Kozikowski AP . Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, Tubastatin A . J. Am. Chem. Soc . 2010 ; 132 ( 31 ): 10842 - 6 .

Zhang XH , Qin M , Wu HP , Khamis MY , Li YH , Ma LY , et al . A review of progress in histone deacetylase 6 inhibitors research: structural specificity and functional diversity . J Med Chem . 2021 ; 64 ( 3 ): 1362 - 91 .

Liu S , Zhang HL , Li J , Ye ZP , Du T , Li LC , et al . Tubastatin A potently inhibits GPX4 activity to potentiate cancer radiotherapy through boosting ferroptosis . Redox Biol . 2023 ; 62 : 102677 .

Amengual JE , Lue JK , Ma H , Lichtenstein R , Shah B , Cremers S , et al . First-in-class selective HDAC6 inhibitor (ACY-1215) has a highly favorable safety profile in patients with relapsed and refractory lymphoma . Oncologist . 2021 ; 26 ( 3 ): 184 - e366 .

Wen Y , Ye S , Li Z , Zhang X , Liu C , Wu Y , et al . HDAC6 inhibitor ACY-1215 enhances STAT1 acetylation to block PD-L1 for colorectal cancer immunotherapy . Cancer Immunol Immunother . 2024 ; 73 ( 1 ): 7 .

Huang P , Almeciga-Pinto I , Jarpe M , van Duzer JH , Mazitschek R , Yang M , et al . Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models . Oncotarget . 2017 ; 8 ( 2 ): 2694 - 707 .

Tsimberidou AM , Beer PA , Cartwright CA , Haymaker C , Vo HH , Kiany S , et al . Preclinical development and first-in-human study of KA2507, a selective and potent inhibitor of histone deacetylase 6, for patients with refractory solid tumors . Clin Cancer Res . 2021 ; 27 ( 13 ): 3584 - 94 .

Rawji V , Latorre A , Sharma N , Rothwell JC , Rocchi L . On the use of TMS to investigate the pathophysiology of neurodegenerative diseases . Front Neurol . 2020 ; 11 : 584664 .

Das S , Murumulla L , Ghosh P , Challa S . Heavy metal-induced disruption of the autophagy-lysosomal pathway: implications for aging and neurodegenerative disorders . BioMetals . 2025 ; 38 ( 2 ): 371 - 417 .

Cha HR , Kim JS , Ryu JH , Cho HJ . Investigating neuroprotective effects of berberine on mitochondrial dysfunction and autophagy impairment in Parkinson’s disease . Int J Mol Sci . 2025 ; 26 ( 15 ): 7342 .

Jomova K , Vondrakova D , Lawson M , Valko M . Metals, oxidative stress and neurodegenerative disorders . Mol Cell Biochem . 2010 ; 345 ( 1-2 ): 91 - 104 .

Valenzuela-Fernández A , Cabrero JR , Serrador JM , Sánchez-Madrid F . HDAC6: a key regulator of cytoskeleton, cell migration and cell-cell interactions . Trends Cell Biol . 2008 ; 18 ( 6 ): 291 - 7 .

Yang XJ , Grégoire S . Class II histone deacetylases: from sequence to function, regulation, and clinical implication . Mol Cell Biol . 2005 ; 25 ( 8 ): 2873 - 84 .

Seidel C , Schnekenburger M , Dicato M , Diederich M . Histone deacetylase 6 in health and disease . Epigenomics . 2015 ; 7 ( 1 ): 103 - 18 .

Francelle L , Outeiro TF , Rappold GA . Inhibition of HDAC6 activity protects dopaminergic neurons from alpha-synuclein toxicity . Sci Rep . 2020 ; 10 ( 1 ): 6064 .

Parmigiani RB , Xu WS , Venta-Perez G , Erdjument-Bromage H , Yaneva M , Tempst P , et al . HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation . Proc Natl Acad Sci U S A . 2008 ; 105 ( 28 ): 9633 - 8 .

Jian W , Wei X , Chen L , Wang Z , Sun Y , Zhu S , et al . Inhibition of HDAC6 increases acetylation of peroxiredoxin1/2 and ameliorates 6-OHDA induced dopaminergic injury . Neurosci Lett . 2017 ; 658 : 114 - 20 .

Yan S , Wei X , Jian W , Qin Y , Liu J , Zhu S , et al . Pharmacological inhibition of HDAC6 attenuates NLRP3 inflammatory response and protects dopaminergic neurons in experimental models of Parkinson’s disease . Front Aging Neurosci . 2020 ; 12 : 78 .

Du Y , Yang X , Li Z , Le W , Hao Y , Song Y , et al . HDAC6-mediated Hsp90 deacetylation reduces aggregation and toxicity of the protein alpha-synuclein by regulating chaperone-mediated autophagy . Neurochem Int . 2021 ; 149 : 105141 .

Pinho BR , Reis SD , Guedes-Dias P , Leitão-Rocha A , Quintas C , Valentão P , et al . Pharmacological modulation of HDAC1 and HDAC6 in vivo in a zebrafish model: therapeutic implications for Parkinson’s disease . Pharmacol Res . 2016 ; 103 : 328 - 39 .

Zhang Y , Liu CM , Cao XC , Zang Y , Zhou YB , Li J . Involvement of transcription factor XBP1s in the resistance of HDAC6 inhibitor Tubastatin A to superoxidation via acetylation-mediated proteasomal degradation . Biochem Biophys Res Commun . 2014 ; 450 ( 1 ): 433 - 9 .

Iwamoto M , Nakamura Y , Takemura M , Hisaoka-Nakashima K , Morioka N . TLR4-TAK1-p38 MAPK pathway and HDAC6 regulate the expression of sigma-1 receptors in rat primary cultured microglia . J Pharmacol Sci . 2020 ; 144 ( 1 ): 23 - 9 .

Ding Y . Histone deacetylases: the critical enzymes for microglial activation involved in neuropathic pain . Front Pharmacol . 2025 ; 16 : 1515787 .

Nath B , Phaneuf D , Julien JP . Axonal transport defect in gigaxonin deficiency rescued by Tubastatin A . Neurotherapeutics . 2023 ; 20 ( 4 ): 1215 - 28 .

Li ZY , Zhang C , Zhang Y , Chen L , Chen BD , Li QZ , et al . A novel HDAC6 inhibitor Tubastatin A: controls HDAC6-p97/VCP-mediated ubiquitination-autophagy turnover and reverses temozolomide-induced er stress-tolerance in GBM cells . Cancer Lett . 2017 ; 391 : 89 - 99 .

DeTure MA , Dickson DW . The neuropathological diagnosis of Alzheimer’s disease . Mol Neurodegener . 2019 ; 14 ( 1 ): 32 .

Fan SJ , Huang FI , Liou JP , Yang CR . The novel histone deacetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer’s disease model . Cell Death Dis . 2018 ; 9 ( 6 ): 655 .

Selenica ML , Benner L , Housley SB , Manchec B , Lee DC , Nash KR , et al . Histone deacetylase 6 inhibition improves memory and reduces total tau levels in a mouse model of tau deposition . Alzheimers Res Ther . 2014 ; 6 ( 1 ): 12 .

Odagiri S , Tanji K , Mori F , Miki Y , Kakita A , Takahashi H , et al . Brain expression level and activity of HDAC6 protein in neurodegenerative dementia . Biochem Biophys Res Commun . 2013 ; 430 ( 1 ): 394 - 9 .

Simões-Pires C , Zwick V , Nurisso A , Schenker E , Carrupt PA , Cuendet M . HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs? . Mol Neurodegener . 2013 ; 8 : 7 .

Zhang L , Liu C , Wu J , Tao JJ , Sui XL , Yao ZG , et al . Tubastatin A/ACY-1215 improves cognition in Alzheimer’s disease transgenic mice . J Alzheimers Dis . 2014 ; 41 ( 4 ): 1193 - 205 .

Ding Y , Kang A , Tang Q , Zhao Y . Inhibition of HDAC6 expression decreases brain injury induced by APOE4 and Aβ co-aggregation in rats . Mol Med Rep . 2019 ; 20 ( 4 ): 3363 - 70 .

Fessler EB , Chibane FL , Wang Z , Chuang DM . Potential roles of HDAC inhibitors in mitigating ischemia-induced brain damage and facilitating endogenous regeneration and recovery . Curr Pharm Des . 2013 ; 19 ( 28 ): 5105 - 20 .

Lisek M , Bochenska N , Tomczak J , Duraj J , Boczek T . Epigenetic regulation in ischemic neuroprotection: the dual role of HDACs and HATs in neuroinflammation and recovery . Antioxidants . 2025 ; 14 ( 8 ): 1015 .

Saijo K , Glass CK . Microglial cell origin and phenotypes in health and disease . Nat Rev Immunol . 2011 ; 11 ( 11 ): 775 - 87 .

Eckert MJ , Martin MJ . Trauma: Spinal cord injury . Surg Clin North Am . 2017 ; 97 ( 5 ): 1031 - 45 .

Wu C , Pan Y , Wang L , Liu M , Tu P , Chen S , et al . Inhibition of HDAC6 promotes microvascular endothelial cells to phagocytize myelin debris and reduces inflammatory response to accelerate the repair of spinal cord injury . CNS Neurosci Ther . 2024 ; 30 ( 3 ): e14439 .

Liao S , Liu Y , Kong Y , Shi H , Xu B , Tang B , et al . A bionic multi-channel nanofiber conduit carrying Tubastatin A for repairing injured spinal cord . Materials Today Bio . 2022 ; 17 : 100454 .

Frąk W , Wojtasińska A , Lisińska W , Młynarska E , Franczyk B , Rysz J . Pathophysiology of cardiovascular diseases: new insights into molecular mechanisms of atherosclerosis, arterial hypertension, and coronary artery disease . Biomedicines . 2022 ; 10 ( 8 ): 1938 .

Yang Z , Wang X , Li L . Vascular age: a narrative review of assessment methods, clinical applications, and future directions . Int J Cardiol Cardiovasc Risk Prev . 2026 ; 29 : 200601 .

Roth GA , Huffman MD , Moran AE , Feigin V , Mensah GA , Naghavi M , et al . Global and regional patterns in cardiovascular mortality from 1990 to 2013 . Circulation . 2015 ; 132 ( 17 ): 1667 - 78 .

Boyault C , Sadoul K , Pabion M , Khochbin S . HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination . Oncogene . 2007 ; 26 ( 37 ): 5468 - 76 .

Wang Y , Miao X , Liu Y , Li F , Liu Q , Sun J , et al . Dysregulation of histone acetyltransferases and deacetylases in cardiovascular diseases . Oxid Med Cell Longev . 2014 ; 2014 : 641979 .

Yang M , Zhang Y , Ren J . Acetylation in cardiovascular diseases: molecular mechanisms and clinical implications . Biochim Biophys Acta Mol Basis Dis .. 2020 ; 1866 ( 10 ): 165836 .

Xu J , Zhao X , Jiang X , He L , Wu X , Wang J , et al . Tubastatin A improves post-resuscitation myocardial dysfunction by inhibiting NLRP3-mediated pyroptosis through enhancing transcription factor EB signaling . J Am Heart Assoc . 2022 ; 11 ( 7 ): e024205 .

Chi Z , Byeon HE , Seo E , Nguyen QT , Lee W , Jeong Y , et al . Histone deacetylase 6 inhibitor Tubastatin A attenuates angiotensin II-induced hypertension by preventing cystathionine γ-lyase protein degradation . Pharmacol Res . 2019 ; 146 : 104281 .

Boucherat O , Chabot S , Paulin R , Trinh I , Bourgeois A , Potus F , et al . HDAC6: a novel histone deacetylase implicated in pulmonary arterial hypertension . Sci Rep . 2017 ; 7 ( 1 ): 4546 .

Song R , Yang Y , Lei H , Wang G , Huang Y , Xue W , et al . HDAC6 inhibition protects cardiomyocytes against doxorubicin-induced acute damage by improving α-tubulin acetylation . J Mol Cell Cardiol . 2018 ; 124 : 58 - 69 .

Leng Y , Wu Y , Lei S , Zhou B , Qiu Z , Wang K , et al . Inhibition of HDAC6 activity alleviates myocardial ischemia/reperfusion injury in diabetic rats: potential role of peroxiredoxin 1 acetylation and redox regulation . Oxid Med Cell Longev . 2018 ; 2018 : 9494052 .

Lassègue B , Griendling KK . Reactive oxygen species in hypertension; an update . Am J Hypertens . 2004 ; 17 ( 9 ): 852 - 60 .

Brandt M , Dörschmann H , Khraisat S , Knopp T , Ringen J , Kalinovic S , et al . Telomere shortening in hypertensive heart disease depends on oxidative DNA damage and predicts impaired recovery of cardiac function in heart failure . Hypertension . 2022 ; 79 ( 10 ): 2173 - 84 .

Pepping JK , Freeman LR , Gupta S , Keller JN , Bruce-Keller AJ . NOX2 deficiency attenuates markers of adiposopathy and brain injury induced by high-fat diet . Am J Physiol Endocrinol Metab . 2013 ; 304 ( 4 ): E392 - 404 .

Cheng X , Fu Z , Xie W , Zhu L , Meng J . Preoperative circulating peroxiredoxin 1 levels as a predictor of non-alcoholic fatty liver disease remission after laparoscopic bariatric surgery . Front Endocrinol . 2022 ; 13 : 1072513 .

DeVallance E , Li Y , Jurczak MJ , Cifuentes-Pagano E , Pagano PJ . The role of NADPH oxidases in the etiology of obesity and metabolic syndrome: contribution of individual isoforms and cell biology . Antioxid Redox Signal . 2019 ; 31 ( 10 ): 687 - 709 .

Fan Lampson M , Cahill-Smith S , Geng L , Du J , Brooks G , Li J-M . Aging-associated metabolic disorder induces Nox2 activation and oxidative damage of endothelial function . Free Radic Biol Med . 2017 ; 108 : 940 - 51 .

Yin W , Wang J , Jiang L , James Kang Y . Cancer and stem cells . Exp Biol Med (Maywood) . 2021 ; 246 ( 16 ): 1791 - 801 .

Cancer: World Health Organization (WHO) ; 2025 https://www.who.int/news-room/fact-sheets/detail/cancer https://www.who.int/news-room/fact-sheets/detail/cancer . Accessed 3 Mar, 2026 .

Siegel RL , Kratzer TB , Giaquinto AN , Sung H , Jemal A . Cancer statistics, 2025 . CA Cancer J Clin . 2025 ; 75 ( 1 ): 10 - 45 .

Baylin SB , Jones PA . A decade of exploring the cancer epigenome – biological and translational implications . Nat Rev Cancer . 2011 ; 11 ( 10 ): 726 - 34 .

Sharma S , Kelly TK , Jones PA . Epigenetics in cancer . Carcinogenesis . 2010 ; 31 ( 1 ): 27 - 36 .

Schnekenburger M , Florean C , Dicato M , Diederich M . Epigenetic alterations as a universal feature of cancer hallmarks and a promising target for personalized treatments . Curr Top Med Chem . 2016 ; 16 ( 7 ): 745 - 76 .

Vaissière T , Sawan C , Herceg Z . Epigenetic interplay between histone modifications and DNA methylation in gene silencing . Mutat Res . 2008 ; 659 ( 1-2 ): 40 - 8 .

Chen P , Zhang YL . Role of HDAC6 in carcinomas . Discov Oncol . 2026 ; 17 ( 1 ): 240 .

Barneda-Zahonero B , Parra M . Histone deacetylases and cancer . Mol Oncol . 2012 ; 6 ( 6 ): 579 - 89 .

Vuletić A , Mirjačić Martinović K , Spasić J . Role of histone deacetylase 6 and histone deacetylase 6 inhibition in colorectal cancer . Pharmaceutics . 2023 ; 16 ( 1 ): 54 .

Li Z , Zhu H , Wang X , Zhang L , Zhang L . Histone deacetylase 6: a potential therapeutic target for drug development . Bioorg Chem . 2025 ; 165 : 108932 .

Gao YS , Hubbert CC , Yao TP . The microtubule-associated histone deacetylase 6 (HDAC6) regulates epidermal growth factor receptor (EGFR) endocytic trafficking and degradation . J Biol Chem . 2010 ; 285 ( 15 ): 11219 - 26 .

Wattanathamsan O , Chantaravisoot N , Wongkongkathep P , Kungsukool S , Chetprayoon P , Chanvorachote P , et al . Inhibition of histone deacetylase 6 destabilizes ERK phosphorylation and suppresses cancer proliferation via modulation of the tubulin acetylation-GRP78 interaction . J Biomed Sci . 2023 ; 30 ( 1 ): 4 .

Kaur S , Rajoria P , Chopra M . HDAC6: a unique HDAC family member as a cancer target . Cell Oncol . 2022 ; 45 ( 5 ): 779 - 829 .

Lian B , Chen X , Shen K . Inhibition of histone deacetylases attenuates tumor progression and improves immunotherapy in breast cancer . Front Immunol . 2023 ; 14 : 1164514 .

Zhou Q , Meng Y , Li D , Yao L , Le J , Liu Y , et al . Ferroptosis in cancer: from molecular mechanisms to therapeutic strategies . Signal Transduct Target Ther . 2024 ; 9 ( 1 ): 55 .

Du L , Zhang Y , Luo J , He C , Lang J , Cao X . Epigenetic and post-translational regulatory networks of ferroptosis in the tumor immune microenvironment . Exp Hematol Oncol . 2026 ; 15 ( 1 ): 11 .

Lei G , Zhuang L , Gan B . Targeting ferroptosis as a vulnerability in cancer . Nat Rev Cancer . 2022 ; 22 ( 7 ): 381 - 96 .

Lang X , Green MD , Wang W , Yu J , Choi JE , Jiang L , et al . Radiotherapy and immunotherapy promote tumoral lipid oxidation and ferroptosis via synergistic repression of SLC7A11 . Cancer Discov . 2019 ; 9 ( 12 ): 1673 - 85 .

Abouhish H , Thounaojam MC , Jadeja RN , Gutsaeva DR , Powell FL , Khriza M , et al . Inhibition of HDAC6 attenuates diabetes-induced retinal redox imbalance and microangiopathy . Antioxidants (Basel) . 2020 ; 9 ( 7 ): 599 .

Saginala K , Barsouk A , Aluru JS , Rawla P , Barsouk A . Epidemiology of melanoma . Med Sci (Basel) . 2021 ; 9 ( 4 ): 63 .

Butrimas G , Šemeklis L , Paukštaitienė R , Dubinskaitė A , Janonytė U , Lukšienė D , et al . Severe sunburns and sunbed use risk with cutaneous melanoma: a case-control study in Lithuania . Medicina (Kaunas) . 2025 ; 61 ( 11 ): 1941 .

Glenn BA , Lin T , Chang LC , Okada A , Wong WK , Glanz K , et al . Sun protection practices and sun exposure among children with a parental history of melanoma . Cancer Epidemiol Biomarkers Prev . 2015 ; 24 ( 1 ): 169 - 77 .

Jeter JM , Bonner JD , Johnson TM , Gruber SB . Nonsteroidal anti-inflammatory drugs and risk of melanoma . J Skin Cancer . 2011 ; 2011 : 598571 .

Mai JZ , Kitahara CM , Sargen MR , Little MP , Alexander BH , Linet MS , et al . Use of nonsteroidal anti-inflammatory drugs and incidence of melanoma in the united states radiologic technologists study . Cancer Prev Res (Phila) . 2022 ; 15 ( 11 ): 727 - 32 .

Nikolaou V , Stratigos AJ . Emerging trends in the epidemiology of melanoma . Br J Dermatol . 2014 ; 170 ( 1 ): 11 - 9 .

Woan KV , Lienlaf M , Perez-Villaroel P , Lee C , Cheng F , Knox T , et al . Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: enhanced antitumor immunity and impaired cell proliferation . Mol Oncol . 2015 ; 9 ( 7 ): 1447 - 57 .

Hino R , Kabashima K , Kato Y , Yagi H , Nakamura M , Honjo T , et al . Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma . Cancer . 2010 ; 116 ( 7 ): 1757 - 66 .

Tomasi TB , Magner WJ , Khan AN . Epigenetic regulation of immune escape genes in cancer . Cancer Immunol Immunother . 2006 ; 55 ( 10 ): 1159 - 84 .

Lienlaf M , Perez-Villarroel P , Knox T , Pabon M , Sahakian E , Powers J , et al . Essential role of HDAC6 in the regulation of PD-L1 in melanoma . Mol Oncol . 2016 ; 10 ( 5 ): 735 - 50 .

Prabhu KS , Sadida HQ , Kuttikrishnan S , Junejo K , Bhat AA , Uddin S . Beyond genetics: exploring the role of epigenetic alterations in breast cancer . Pathol Res Pract . 2024 ; 254 : 155174 .

Li A , Chen P , Leng Y , Kang J . Histone deacetylase 6 regulates the immunosuppressive properties of cancer-associated fibroblasts in breast cancer through the STAT3-COX2-dependent pathway . Oncogene . 2018 ; 37 ( 45 ): 5952 - 66 .

Aldana-Masangkay GI , Sakamoto KM . The role of HDAC6 in cancer . J Biomed Biotechnol . 2011 ; 2011 : 875824 .

Yuan YG , Peng QL , Gurunathan S . Combination of palladium nanoparticles and tubastatin-A potentiates apoptosis in human breast cancer cells: a novel therapeutic approach for cancer . Int J Nanomedicine . 2017 ; 12 : 6503 - 20 .

Jovčevska I , Kočevar N , Komel R . Glioma and glioblastoma – how much do we (not) know? . Mol Clin Oncol . 2013 ; 1 ( 6 ): 935 - 41 .

Urdiciain A , Erausquin E , Meléndez B , Rey JA , Idoate MA , Castresana JS . Tubastatin A, an inhibitor of HDAC6, enhances temozolomide-induced apoptosis and reverses the malignant phenotype of glioblastoma cells . Int J Oncol . 2019 ; 54 ( 5 ): 1797 - 808 .

Pezzotta A , Brioschi L , Carbone S , Mazzoleni B , Bontempi V , Monastra F , et al . Combined inhibition of hedgehog and HDAC6: in vitro and in vivo studies reveal a new role for lysosomal stress in reducing glioblastoma cell viability . Int J Mol Sci . 2023 ; 24 ( 6 ): 5771 .

Zhang G , Gan YH . Synergistic antitumor effects of the combined treatment with an HDAC6 inhibitor and a COX-2 inhibitor through activation of PTEN . Oncol Rep . 2017 ; 38 ( 5 ): 2657 - 66 .

Kozyreva VK , McLaughlin SL , Livengood RH , Calkins RA , Kelley LC , Rajulapati A , et al . NEDD9 regulates actin dynamics through cortactin deacetylation in an AURKA/HDAC6-dependent manner . Mol Cancer Res . 2014 ; 12 ( 5 ): 681 - 93 .

Tzika E , Dreker T , Imhof A . Epigenetics and metabolism in health and disease . Front Genet . 2018 ; 9 : 361 .

Phillips CM . Metabolically healthy obesity: personalised and public health implications . Trends Endocrinol Metab . 2016 ; 27 ( 4 ): 189 - 91 .

Nl S , Shakhatreh Z , Tahir A , Singh J , Sulaiman S , H A , et al . Epigenetic mechanisms in the transfer of metabolic disorders: a comprehensive review . Cureus . 2025 ; 17 ( 3 ): e80418 .

Wu YL , Lin ZJ , Li CC , Lin X , Shan SK , Guo B , et al . Epigenetic regulation in metabolic diseases: mechanisms and advances in clinical study . Signal Transduct Target Ther . 2023 ; 8 ( 1 ): 98 .

Cedernaes J , Osler ME , Voisin S , Broman JE , Vogel H , Dickson SL , et al . Acute sleep loss induces tissue-specific epigenetic and transcriptional alterations to circadian clock genes in men . J Clin Endocrinol Metab . 2015 ; 100 ( 9 ): E1255 - 61 .

Morris CJ , Purvis TE , Mistretta J , Scheer FA . Effects of the internal circadian system and circadian misalignment on glucose tolerance in chronic shift workers . J Clin Endocrinol Metab . 2016 ; 101 ( 3 ): 1066 - 74 .

McKay JA , Mathers JC . Diet induced epigenetic changes and their implications for health . Acta Physiol (Oxf) . 2011 ; 202 ( 2 ): 103 - 18 .

Borrego-Ruiz A , Borrego JJ . Epigenetic mechanisms in aging: extrinsic factors and gut microbiome . Genes . 2024 ; 15 ( 12 ): 1599 .

van Dijk SJ , Tellam RL , Morrison JL , Muhlhausler BS , Molloy PL . Recent developments on the role of epigenetics in obesity and metabolic disease . Clin Epigenetics . 2015 ; 7 : 66 .

Peleg S , Feller C , Ladurner AG , Imhof A . The metabolic impact on histone acetylation and transcription in ageing . Trends Biochem Sci . 2016 ; 41 ( 8 ): 700 - 11 .

Su M , Gong X , Liu F . An update on the emerging approaches for histone deacetylase (HDAC) inhibitor drug discovery and future perspectives . Expert Opin Drug Discov . 2021 ; 16 ( 7 ): 745 - 61 .

Zhang WB , Yang F , Wang Y , Jiao FZ , Zhang HY , Wang LW , et al . Inhibition of HDAC6 attenuates LPS-induced inflammation in macrophages by regulating oxidative stress and suppressing the TLR4-MAPK/NF-κB pathways . Biomed Pharmacother . 2019 ; 117 : 109166 .

Zhang WB , Zhang HY , Jiao FZ , Wang LW , Zhang H , Gong ZJ . Histone deacetylase 6 inhibitor ACY-1215 protects against experimental acute liver failure by regulating the TLR4-MAPK/NF-κB pathway . Biomed Pharmacother . 2018 ; 97 : 818 - 24 .

Zhang L , Zhang Z , Li C , Zhu T , Gao J , Zhou H , et al . S100A11 promotes liver steatosis via FOXO1-mediated autophagy and lipogenesis . Cell Mol Gastroenterol Hepatol . 2021 ; 11 ( 3 ): 697 - 724 .

Cavadas C , Aveleira CA , Souza GF , Velloso LA . The pathophysiology of defective proteostasis in the hypothalamus – from obesity to ageing . Nat Rev Endocrinol . 2016 ; 12 ( 12 ): 723 - 33 .

Osseni A , Ravel-Chapuis A , Belotti E , Scionti I , Gangloff YG , Moncollin V , et al . Pharmacological inhibition of HDAC6 improves muscle phenotypes in dystrophin-deficient mice by downregulating TGF-β via Smad3 acetylation . Nat Commun . 2022 ; 13 ( 1 ): 7108 .

Agrawal A , Clayton EL , Cavazos CL , Clayton BA , Rodney GG . Histone deacetylase 6 inhibition promotes microtubule acetylation and facilitates autophagosome-lysosome fusion in dystrophin-deficient mdx mice . Acta Physiol (Oxf) . 2025 ; 241 ( 1 ): e14243 .

Shrestha P , Duwa R , Lee S , Kwon TK , Jeong JH , Yook S . ROS-responsive thioketal nanoparticles delivering system for targeted ulcerative colitis therapy with potent HDAC6 inhibitor, Tubastatin A . Eur J Pharm Sci . 2024 ; 201 : 106856 .

Seo HY , Park JY , Lee SH , Cho SH , Han E , Hwang JS , et al . Clusterin inhibits lipopolysaccharide induced liver injury . Sci Rep . 2025 ; 15 ( 1 ): 5975 .

Wang J , Zhao L , Wei Z , Zhang X , Wang Y , Li F , et al . Inhibition of histone deacetylase reduces lipopolysaccharide-induced-inflammation in primary mammary epithelial cells by regulating ROS-NF-кB signaling pathways . Int Immunopharmacol . 2018 ; 56 : 230 - 4 .

Pant K , Richard S , Peixoto E , Baral S , Yang R , Ren Y , et al . Cholangiocyte ciliary defects induce sustained epidermal growth factor receptor signaling . Hepatology . 2025 ; 81 ( 4 ): 1132 - 45 .

Obed A , Alsakarneh S , Abuassi M , Bashir A , Ahmad BA , Jarrad A , et al . Ischemic reperfusion injury after liver transplantation: is there a place for conservative management? . Gastroenterology Res . 2023 ; 16 ( 1 ): 50 - 5 .

Ito T , Naini BV , Markovic D , Aziz A , Younan S , Lu M , et al . Ischemia-reperfusion injury and its relationship with early allograft dysfunction in liver transplant patients . Am J Transplant . 2021 ; 21 ( 2 ): 614 - 25 .

Concors SJ , Hernandez PT , O'Brien C , DePaolo J , Murken DR , Aufhauser DD , et al . Differential effects of HDAC6 inhibition versus knockout during hepatic ischemia-reperfusion injury highlight importance of HDAC6 C-terminal zinc-finger ubiquitin-binding domain . Transplantation . 2024 ; 108 ( 10 ): 2084 - 92 .

Kechida M . Update on autoimmune diseases pathogenesis . Curr Pharm Des . 2019 ; 25 ( 27 ): 2947 - 52 .

Farh KK , Marson A , Zhu J , Kleinewietfeld M , Housley WJ , Beik S , et al . Genetic and epigenetic fine mapping of causal autoimmune disease variants . Nature . 2015 ; 518 ( 7539 ): 337 - 43 .

Mu S , Wang W , Liu Q , Ke N , Li H , Sun F , et al . Autoimmune disease: a view of epigenetics and therapeutic targeting . Front Immunol . 2024 ; 15 : 1482728 .

Oh BR , Suh D-h , Bae D , Ha N , Choi YI , Yoo HJ , et al . Therapeutic effect of a novel histone deacetylase 6 inhibitor, CKD-L, on collagen-induced arthritis in vivo and regulatory T cells in rheumatoid arthritis in vitro . Arthritis Res Ther . 2017 ; 19 ( 1 ): 154 .

Ahmed S , Riegsecker S , Beamer M , Rahman A , Bellini JV , Bhansali P , et al . Largazole, a class I histone deacetylase inhibitor, enhances TNF-α-induced ICAM-1 and VCAM-1 expression in rheumatoid arthritis synovial fibroblasts . Toxicol Appl Pharmacol . 2013 ; 270 ( 2 ): 87 - 96 .

Vishwakarma S , Iyer LR , Muley M , Singh PK , Shastry A , Saxena A , et al . Tubastatin, a selective histone deacetylase 6 inhibitor shows anti-inflammatory and anti-rheumatic effects . Int Immunopharmacol . 2013 ; 16 ( 1 ): 72 - 8 .

Jiayin Z , Meizhu Z , Yi Z , Jie Z . Dietary fibre intervention in Hashimoto's thyroiditis patients and its impact on the gut microbiota . Clin Nutr Open Sci . 2025 ; 60 : 250 - 61 .

Chang Q , Yin D , Li H , Du X , Wang Z , Liu Y , et al . HDAC6-specific inhibitor alleviates hashimoto's thyroiditis through inhibition of Th17 cell differentiation . Mol Immunol . 2022 ; 149 : 39 - 47 .

Quan J , Ma C , Zhao X , Guo Y , Qu W , Zhou X , et al . Discovery of novel selective HDAC6 inhibitors via a scaffold hopping approach for the treatment of idiopathic pulmonary fibrosis (IPF) in vitro and in vivo . Bioorg Chem . 2025 ; 159 : 108360 .

Singh SK , Tanwar SS , Patel D , Yadav P , Rajput S , Sharma A , et al . Epigenetics of idiopathic pulmonary fibrosis . In: Gupta G , Oliver BG , Dua K , Ali MK , Dave P , editors. Targeting epigenetics in inflammatory lung diseases . Singapore : Springer Nature ; 2023 . p. 145 - 74 .

Saito S , Zhuang Y , Shan B , Danchuk S , Luo F , Korfei M , et al . Tubastatin ameliorates pulmonary fibrosis by targeting the TGFβ-PI3K-Akt pathway . PLoS One . 2017 ; 12 ( 10 ): e0186615 .

Liu Y , Wang R , Han H , Li L . Tubastatin A suppresses the proliferation of fibroblasts in epidural fibrosis through phosphatidylinositol-3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) signalling pathway . J Pharm Pharmacol . 2022 ; 74 ( 3 ): 426 - 34 .

Zhou T , Jia D , Han J , Xu C , You X , Ge X . HDAC6 inhibition alleviates acute pulmonary embolism: a possible future therapeutic option . Folia Histochem Cytobiol . 2023 ; 61 ( 1 ): 56 - 67 .

Deng Q , Zhao T , Pan B , Dennahy IS , Duan X , Williams AM , et al . Protective effect of Tubastatin A in CLP-induced lethal sepsis . Inflammation . 2018 ; 41 : 2101 - 9 .

Gagliardi S , Hotchkin T , Hillmer G , Engelbride M , Diggs A , Tibebe H , et al . Oxidative stress in HIV-associated neurodegeneration: mechanisms of pathogenesis and therapeutic targets . Int J Mol Sci . 2025 ; 26 ( 14 ): 6724 .

Youn GS , Cho H , Kim D , Choi SY , Park J . Crosstalk between HDAC6 and Nox2-based NADPH oxidase mediates HIV-1 Tat-induced pro-inflammatory responses in astrocytes . Redox Biol . 2017 ; 12 : 978 - 86 .

Kozlov MV , Kleymenova AA , Konduktorov KA , Malikova AZ , Kochetkov SN . Selective inhibitor of histone deacetylase 6 (Tubastatin A) suppresses proliferation of hepatitis C virus replicon in culture of human hepatocytes . Biochemistry (Mosc) . 2014 ; 79 ( 7 ): 637 - 42 .

Kageyama K , Oki Y , Sakihara S , Nigawara T , Terui K , Suda T . Evaluation of the diagnostic criteria for Cushing's disease in Japan . Endocr J . 2013 ; 60 ( 2 ): 127 - 35 .

Nigawara T , Iwasaki Y , Asai M , Yoshida M , Kambayashi M , Sashinami H , et al . Inhibition of 11β-hydroxysteroid dehydrogenase eliminates impaired glucocorticoid suppression and induces apoptosis in corticotroph tumor cells . Endocrinology . 2006 ; 147 ( 2 ): 769 - 72 .

Hagiwara R , Kageyama K , Iwasaki Y , Niioka K , Daimon M . Effects of Tubastatin A on adrenocorticotropic hormone synthesis and proliferation of AtT-20 corticotroph tumor cells . Endoc J . 2022 ; 69 ( 9 ): 1053 - 60 .

Leyk J , Daly C , Janssen-Bienhold U , Kennedy BN , Richter-Landsberg C . HDAC6 inhibition by Tubastatin A is protective against oxidative stress in a photoreceptor cell line and restores visual function in a zebrafish model of inherited blindness . Cell Death Dis . 2017 ; 8 ( 8 ): e3028 .

Chatelain E , Ioset JR . Phenotypic screening approaches for Chagas disease drug discovery . Expert Opin Drug Discov . 2018 ; 13 ( 2 ): 141 - 53 .

Duraisingh MT , Horn D . Epigenetic regulation of virulence gene expression in parasitic protozoa . Cell Host Microbe . 2016 ; 19 ( 5 ): 629 - 40 .

de Oliveira Santos J , Zuma AA , de Souza W , Motta MCM . Tubastatin A, a deacetylase inhibitor, as a tool to study the division, cell cycle and microtubule cytoskeleton of trypanosomatids . Eur J Protistol . 2021 ; 80 : 125821 .

Subramanian C , Jarzembowski JA , Jr Opipari AW , Castle VP , Kwok RP . HDAC6 deacetylates Ku70 and regulates Ku70-Bax binding in neuroblastoma . Neoplasia . 2011 ; 13 ( 8 ): 726 - 34 .

Zhang SY , Zhang LY , Wen R , Yang N , Zhang TN . Histone deacetylases and their inhibitors in inflammatory diseases . Biomed Pharmacother . 2024 ; 179 : 117295 .

Karagiannis D , Rampias T . HDAC inhibitors: dissecting mechanisms of action to counter tumor heterogeneity . Cancers (Basel) . 2021 ; 13 ( 14 ): 3575 .

Reddy RG , Surineni G , Bhattacharya D , Marvadi SK , Sagar A , Kalle AM , et al . Crafting carbazole-based vorinostat and tubastatin-A-like histone deacetylase (HDAC) inhibitors with potent in vitro and in vivo neuroactive functions . ACS Omega . 2019 ; 4 ( 17 ): 17279 - 94 .

浏览量

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

Associations of different definitions of prediabetes and diabetes with all-cause and cause-specific mortality: a nationally representative cohort study

Global patterns and trends in cancer-related premature death and their impact on life expectancy across 185 countries: a population-based analysis

The national and provincial prevalence and non-fatal burdens of diabetes in China from 2005 to 2023 with projections of prevalence to 2050

Unresolved questions in the application of artificial intelligence virtual cells for cancer research

Impact of targeting the platelet-activating factor and its receptor in cancer treatment